Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.80% | 8.68% | -40.78% | 34.15% | -49.73% |
| Total Depreciation and Amortization | -- | -100.00% | -88.37% | 330.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.33% | -30.20% | 223.22% | -116.94% | 1,068.70% |
| Change in Net Operating Assets | 151.72% | 117.10% | -164.24% | -319.19% | 372.88% |
| Cash from Operations | 14.80% | 34.25% | -32.06% | -72.26% | 24.31% |
| Capital Expenditure | 0.00% | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -280.87% | -- | -- | -163.98% | 551.31% |
| Cash from Investing | -280.97% | -- | -- | -163.98% | 552.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -49.71% | 69,500.00% | -100.00% | 25,428.24% | 1,316.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.71% | 69,500.00% | -99.99% | 22,275.82% | 1,316.67% |
| Foreign Exchange rate Adjustments | -132.02% | 16,033.33% | -98.99% | -2.33% | 223.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -443.56% | 174.79% | -130.10% | 139.53% | 504.72% |